Are HIFU, Cryotherapy, or IRE Alternatives to Surgery for Prostate Cancer?

Is HIFU an effective treatment for localized prostate cancer?

HIFU can control cancer for some carefully selected people, but its long-term place beside surgery and radiation is not settled. The critical distinction is between a promising treatment result and proof that it delivers the same cancer control as established whole-gland options. The 2026 AUA/ASTRO guideline says that proof is not yet available.

Focal therapy treats a chosen area of the prostate rather than the entire gland. That separates it from radical prostatectomy and radiation therapy, which are whole-gland treatments, and from active surveillance, which is a standard-of-care comparator named in the guideline rather than an ablative treatment. The intended tradeoff is function preservation versus more intensive surveillance for cancer left in, or returning within, the remaining prostate tissue.

HIFU uses high-intensity therapeutic ultrasound to thermally ablate a defined target volume under imaging guidance. The FDA's 2015 Sonablate 450 classification describes it as a prescription device for ablation of prostatic tissue, while explicitly stating that the classification is not an indication to treat a specific prostate disease. Device availability is not the same thing as comparative evidence.

The results show why the conversation needs precision. In the prospective multicentre focal-HIFU study of 625 men, the five-year outcome report found 88% failure-free survival, defined as avoiding radical or systemic therapy, metastases, and prostate-cancer death; metastasis-free survival was 98%, cancer-specific survival was 100%, and overall survival was 99% at the five-year endpoint. Among the 247 men who returned continence questionnaires, 98% were pad-free at that five-year follow-up, according to the European Urology study.

That is encouraging. It does not answer the surgery-versus-HIFU question by itself, because the AUA/ASTRO guideline says high-quality direct comparisons with surgery, radiation, and active surveillance are lacking.

Who is a candidate for focal therapy instead of prostate removal or radiation?

A candidate is someone whose cancer appears sufficiently localized and whose priorities, follow-up capacity, and fallback options all fit a focal strategy; focal ablation is not recommended for high-risk prostate cancer outside a clinical trial under the 2026 AUA/ASTRO guideline. This is selection work, not a shortcut.

The prospective focal-HIFU trial gives a concrete example of how selective protocols can be. Its 91 participants had no more than two lesions, Grade Group 3 or lower disease, PSA of 15 ng/mL or lower, clinical stage T1c to T2, and life expectancy of at least 10 years. Those are trial entry criteria, not a universal checklist.

Different focal approaches have different evidence bases and protocols. Cryotherapy uses needles placed at the tumor site to create ice balls that freeze tumor cells. The NCI-listed focal cryotherapy trial for intermediate-risk disease targets the known tumor area and adjacent tissue, with negative in-field recurrence on six-month biopsy as its primary endpoint. It also measures out-of-field recurrence and financial toxicity, a useful reminder that the treatment decision includes both cancer control and practical cost exposure.

For IRE, the prospective 123-person cohort reported 96.75% failure-free survival and 99% metastasis-free survival at the three-year endpoint, with 18 people receiving salvage treatment. In-field recurrence on post-treatment biopsy ranged from 2.7% to 9.8% in that cohort, according to the European Urology Oncology study. These outcomes are useful context, not a head-to-head verdict: the 2026 AUA/ASTRO guideline says no trials directly compare the ablative approaches with one another.

Use a plan-before-procedure check in the consultation. The useful questions are: “How many focal cases using this technique has this team followed through biopsy?” “What exact PSA, MRI, and biopsy schedule will apply?” “Is there a relevant clinical trial?” “What financial costs are not covered?” and “If biopsy finds persistent cancer, which salvage treatment is planned?” These questions lower cognitive load because they turn an attractive treatment label into an operational plan.

How does HIFU compare with surgery for cancer control and side effects?

HIFU may offer a function-preservation advantage for selected patients, but it cannot currently be presented as cancer-control equivalent to surgery. The 2026 AUA/ASTRO guideline is direct: low- and intermediate-risk patients should be told focal and whole-gland ablation remain investigational without high-quality comparisons to surgery, radiation, and active surveillance.

The function data are meaningful but need their proper frame. In the 91-person prospective focal-HIFU trial, 21% reported meaningful worsening in erectile function at the three-year endpoint, while 81% avoided whole-gland treatment at that same three-year endpoint. The trial also found that, depending on the definition of failure, failure-free survival was 44% or 65% at three years. Definitions matter. A broad “avoided whole-gland treatment” result answers a different question from a biopsy-based cancer-control result.

The surveillance burden is the other half of the bargain. In that HIFU trial, 83 of 91 participants had at least one follow-up biopsy. MRI had a negative predictive value of up to 89%, but PSA change and MRI performed poorly for detecting residual disease. The IRE cohort made the same practical point: MRI sensitivity for in-field residual disease was 40% at the six-month assessment despite a 94% negative predictive value. A reassuring scan does not erase the role of planned biopsy.

Weak framing: “Focal therapy avoids surgery.” Strong framing: “Focal therapy may defer or avoid whole-gland treatment for some people, while committing them to PSA testing, MRI, and biopsy, with surgery or radiation available if biopsy documents recurrence.” The second sentence is less tidy. It is also the real decision.

If cancer returns after focal ablation and salvage local treatment is being considered, the AUA/ASTRO/SUO salvage guideline says clinicians should offer whole-gland radical prostatectomy or radiation therapy. That plan belongs in the initial discussion, not in the fine print after an abnormal biopsy.